Reece T Brett, Tribble Curtis G, Okonkwo David O, Davis Jonathon D, Maxey Thomas S, Gazoni Leo M, Linden Joel, Kron Irving L, Kern John A
Department of Surgery, University of Virginia, Charlottesville, Virginia, USA.
J Cardiovasc Med (Hagerstown). 2008 Apr;9(4):363-7. doi: 10.2459/JCM.0b013e3282eee836.
Adenosine receptor activation at reperfusion has been shown to ameliorate ischemia-reperfusion injury of the spinal cord, but the effects of therapy given in response to ischemic injury are unknown. We hypothesized that adenosine receptor activation with ATL-146e would produce similar protection from ischemic spinal cord injury, whether given at reperfusion or in a delayed fashion.
Twenty-two New Zealand white rabbits were divided into three groups. All three groups, including the ischemia-reperfusion group (IR, n = 8), underwent 45 min of infrarenal aortic occlusion. The early treatment group (early, n = 8) received 0.06 mug/kg/min of ATL-146e for 3 h beginning 10 min prior to reperfusion. The delayed treatment group (delayed, n = 6) received ATL-146e starting 1 h after reperfusion. After 48 h, hind limb function was graded using the Tarlov score. Finally, lumbar spinal cord neuronal cytoarchitecture was evaluated.
Hemodynamic parameters were similar among the groups. Hind limb function at 48 h was significantly better in the early group (3.5 +/- 1.0) compared to the IR group (0.625 +/- 0.5, P < or = 0.01). There was a trend towards better hind limb function in the early group compared to the delayed group (2.4 +/- 1.1, P = 0.08). Hind limb function was similar between delayed and IR groups. Hematoxylin-eosin spinal cord sections demonstrated preservation of viable motor neurons in the early group compared to the delayed and IR groups.
Early therapy with ATL-146e provided better protection in this study; therefore, therapy should not be delayed until there is evidence of ischemic neurological deficit. This study suggests that adenosine receptor activation is most effective as a preventive strategy at reperfusion for optimal protection in spinal cord ischemia-reperfusion injury.
已表明再灌注时腺苷受体激活可改善脊髓缺血再灌注损伤,但针对缺血损伤所给予治疗的效果尚不清楚。我们推测,无论在再灌注时给予还是延迟给予,用ATL - 146e激活腺苷受体都会对缺血性脊髓损伤产生类似的保护作用。
22只新西兰白兔分为三组。所有三组,包括缺血再灌注组(IR,n = 8),均接受45分钟的肾下腹主动脉阻断。早期治疗组(early,n = 8)在再灌注前10分钟开始以0.06微克/千克/分钟的剂量给予ATL - 146e,持续3小时。延迟治疗组(delayed,n = 6)在再灌注后1小时开始给予ATL - 146e。48小时后,使用塔尔洛夫评分对后肢功能进行分级。最后,评估腰段脊髓神经元细胞结构。
各组间血流动力学参数相似。与IR组(0.625±0.5)相比,早期组在48小时时的后肢功能明显更好(3.5±1.0,P≤0.01)。与延迟组(2.4±1.1,P = 0.08)相比,早期组后肢功能有更好的趋势。延迟组和IR组之间后肢功能相似。苏木精 - 伊红染色的脊髓切片显示,与延迟组和IR组相比,早期组中存活的运动神经元得以保留。
在本研究中,早期用ATL - 146e治疗提供了更好保护;因此,治疗不应延迟至出现缺血性神经功能缺损的证据。本研究表明,在脊髓缺血再灌注损伤中,腺苷受体激活作为一种预防性策略在再灌注时最为有效,可实现最佳保护。